Loading clinical trials...

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine | Clinical Trials | Clareo Health

COMPLETED

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

NCT00772473•Clinvest

View on ClinicalTrials.gov

Summary

To assess CGRP levels in saliva through the evolution of migraine.

Detailed Description

The release of CGRP is assumed to be initiated early in the migraine process and increases as the headache intensifies. Levels of CGRP will be measured during the premonitory, mild, moderate, and severe phases of a single migraine attack and compared to the baseline value determined when the subject was headache free. Understanding of the clinical evolution of migraine CGRP release may have significant implications in acute treatment.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ability to read, understand, and sign the informed consent
•2. Subject is between the ages of 18 and 65, either male or female
•3. Negative pregnancy test for those of childbearing potential.
•4. Adequate birth control as approved by the investigator if of childbearing potential
•5. Subjects must fulfill criteria for IHS migraine (1.1 or 1.2) with a history of 1-6 migraines per month within the past 3 months and at least 15 headache free days though out the previous three month time period

Exclusion Criteria

•1. Pregnant or breast feeding
•2. Presence of any condition or symptoms that would knowingly alter the content of the saliva
•3. Presence of any medical disease or condition that would interfere with the conduct of the study
•4. Current use of other medications that would be contraindicated in those patients that will take triptan medications for treatment of migraine symptoms, ie. MAO inhibitors, lithium, methyergonovine, methysergide, or ergotamine-containing products
•5. Use of migraine preventive medications in the three months prior to screening
•6. History of drug or alcohol abuse that would interfere with the study
•7. Any pathology of the salivary glands such as sialadenitis (e.g., Sjorgen's syndrome, viral or bacterial sialadenitis, obstructive sialadentitis)
•8. History of hypersensitivity or allergy to triptan medications
•9. Presence of diabetes, salivary gland tumors, liver disease, alcoholism, and neuropathy
•10. More than 15 days per month of headache within the past 3 months
+1 more criteria

Locations (1)

Clinvest

Springfield, Missouri, United States

Key Dates

Start Date

February 1, 2008

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

May 25, 2009

Enrollment

ACTUAL participants

Conditions

Headache, Migraine

Interventions

subjects personal triptan

OTHER

Mind Body Balance for Pediatric Migraine

NCT04715685

HeadacheHeadache Disorders+6 more

View study

RECRUITINGNA

Trial Designs for Evaluating Migraine Treatment

NCT06617832

Migraine with AuraMigraine Without Aura+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 25, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine

Inclusion Criteria

Exclusion Criteria

Mind Body Balance for Pediatric Migraine

Trial Designs for Evaluating Migraine Treatment

Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption

Adolescent Lifestyle Medicine Headache Study

Intranasal Ketorolac Trial

Mind and Body Approaches to Pain Reduction in Youth With Migraine